Abstract 770
Background
Metronomic chemotherapy is one of the proven methods for treatment of terminally ill patients with malignancy, who are otherwise not fit for chemotherapy. The literature (IJMPO 2013:34 11-15) suggested that it has been used in patients with PS1/2. However, it was never used in PS 3 and above and it is worth exploring the same as the adverse event profile was very limited with the treatment. With encouraging results of above publications, we explored the possibility of using Gefitinib methotrexate 15 mg either alone or in combination in patients with advanced head and neck cancers in view of the limited options and literature availability for subjects with PS 3 and more.
Methods
Aim- Analysis of Gefitinib 250 mg once a day vs methotrexate 15 mg once a week vs combination in patients with advanced head and neck cancers safety and efficacy. We collected the details of the 78 subjects with pre-treated advanced refractory or progressive solid tumors having PS of more than 2. Case records between 2017 September and 2018 September were analyzed, 78 patients were found suitable for analysis. Patients received gefitinib (250 mg/day), methotrexate as 15 mg intramuscular weekly or a combination. Patients were stratified into those with improved PS and those without. The subjects without PS improvement were continued on the single agent and those with improvement were offered additional chemotherapy based on the primary site.
Results
Out of 78 subjects, 49 had improvement in the PS and were continued later. 19 subjects had stable PS and disease. 10 subjects had worsening of PS. Fifty-two subjects have clinically meaningful response (stable disease + complete + partial responses) and had symptomatic improvement. The median PFS was 248 days (95% CI, 104 to 282), and the median improvement in QOL was 9 points on a scale of 30.
Conclusions
Gefitinib 250 mg once a day, methotrexate 15 mg once a week, or combination is well tolerated and may have a role in the treatment of advanced cancers with poor performance status. Majority of the patients who are otherwise not eligible beyond palliative care now had better QOL and longer PFS, which re-emphasizes role of metronomic therapy in advanced squamous cell carcinoma of head and neck regions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract